Key result
Preoperative use of ACEIs before CABG surgery increased the risk of hypotension, postoperative myocardial infarction, and renal dysfunction.
Why the study?
Does preoperative administration of ACEIs affect clinical outcomes and safety in patients undergoing CABG surgery?
Systematic Review (n=31,390)
Does preoperative administration of ACEIs affect clinical outcomes and safety in patients undergoing CABG surgery?
Preoperative administration of ACE inhibitors before CABG surgery increases the risk of postoperative hypotension, myocardial infarction, and renal dysfunction without improving early mortality.
Answers are grounded in this paper and cite their sources.
Preoperative ACEI use may increase postoperative MI risk in CABG; challenges routine continuation and leaves open need for RCTs.
The safety of the preoperative administration of angiotensin-converting enzyme inhibitors (ACEIs) in patients undergoing coronary artery bypass grafting (CABG) surgery is still uncertain. This systematic review thus evaluated the effect of preoperative ACEIs on the clinical outcomes in patients undergoing CABG surgery. We searched PubMed, the Cochrane Library and the Web of Science for randomized control trials or observational studies that compared the use of ACEIs with that of placebos before isolated CABG. Thirteen studies (3 randomized control trials and 10 observational studies) that included 31 390 patients met the eligibility criteria. Preoperative ACEI treatment increased the risk of hypotension [risk ratio (RR) = 2.36, 95% confidence interval (CI) 1.11-5.02, P = 0.03], postoperative myocardial infarction (RR = 1.14, 95% CI 1.02-1.27, P = 0.02) and postoperative renal dysfunction (RR = 1.26, 95% CI 1.00-1.60, P = 0.05) in patients undergoing on-pump CABG, but had no significant impact on the risk of postoperative atrial fibrillation (RR = 0.79, 95% CI 0.37-1.71, P = 0.56) or postoperative stroke (RR = 1.17, 95% CI 0.74-1.85, P = 0.50), and did not influence the early mortality (RR = 1.21, 95% CI 0.95-1.54, P = 0.12) in patients undergoing on-pump CABG. Preoperative use of ACEIs increased the risk of several postoperative complications in patients undergoing CABG. Further randomized studies are needed to more clearly elucidate the risks and benefits of ACEI therapy before CABG.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2014) conducted a systematic review in Coronary artery bypass grafting (CABG) surgery (n=31,390). Preoperative angiotensin-converting enzyme inhibitors (ACEIs) vs. Placebo was evaluated on Hypotension (RR 2.36, 95% CI 1.11-5.02, p=0.03). Preoperative use of ACEIs before CABG surgery increased the risk of hypotension, postoperative myocardial infarction, and renal dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: